Mikkel Terp

Associate Professor

University of Southern Denmark

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mikkel Terp is an Associate Professor at the University of Southern Denmark. His research focuses on cancer therapy and resistance mechanisms, with recent publications exploring topics such as adoptive cell transfer therapy, the apoptotic fate of cancer cells under various inhibitors, and the role of myeloid-derived suppressor cells in breast cancer. Dr. Terp's work aims to improve treatment strategies for triple-negative and hormone-resistant breast cancers through innovative therapeutic approaches.

Articles (14)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

morten gjerstorff

Professor

University of Southern Denmark

DENMARK

View details

Annette Raskov Kodahl

Odense University Hospital

DENMARK

View details

Jean Albrengues

INSERM Délégation régionale Provence Alpes Cote d'Azur et Corse

FRANCE

View details

Martina Tuttolomondo

Assistant Professor

University of Southern Denmark

DENMARK

View details

Henrik J. Ditzel

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mikkel Terp

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.

Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation.

PDX Models: A Versatile Tool for Studying the Role of Myeloid-Derived Suppressor Cells in Breast Cancer

DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1.

SSX addiction in melanoma propagates tumor growth and metastasis.

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.

ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta.

HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer.

DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma.

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells.

Collaborators (5)

morten gjerstorff

Annette Raskov Kodahl

Jean Albrengues

Martina Tuttolomondo

Henrik J. Ditzel

Make your next move.